BLU-5937

Small molecule

Also known as GSK5464714

Earlyevidence

Evidence outlook

Irritable Bowel Syndrome: mid-stage studies underway, no completed readout

In Irritable Bowel Syndrome, Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. Studies in other indications have read out; see the trials and Regulatory events below.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (3)
Other / comorbidity
NCT07650084 · GlaxoSmithKline
2025-11-21 – 2028-06-02 · Refractory Chronic Cough
What this study did
NCT05600777 · Bellus Health Inc. - a GSK company
2022-12-05 – 2027-03-17 · Cough, Refractory Chronic Cough
What this study did
NCT05599191 · Bellus Health Inc. - a GSK company
2022-10-25 – 2026-06-18 · Cough, Refractory Chronic Cough
What this study did
Phase 2 (4)
Irritable Bowel Syndrome
Other / comorbidity
NCT04678206 · Bellus Health Inc. - a GSK company
2020-12-07 – 2021-11-02 · Refractory Chronic Cough
What this study did
NCT04693195 · Bellus Health Inc. - a GSK company
2020-12-09 – 2021-10-12 · Chronic Pruritus, Atopic Dermatitis
What this study did
NCT03979638 · Bellus Health Inc. - a GSK company
2019-07-10 – 2020-04-23 · Chronic Refractory Cough
What this study did
Phase 1 (9)
Other / comorbidity
NCT07684586 · GlaxoSmithKline
2026-07-02 – 2027-08-27 · Cough
What this study did
NCT06222892 · Bellus Health Inc. - a GSK company
2024-02-02 – 2024-12-30 · Cough
What this study did
NCT06497517 · Bellus Health Inc. - a GSK company
2024-07-09 – 2024-08-26 · Cough
What this study did
NCT05570539 · Bellus Health Inc. - a GSK company
2022-10-07 – 2024-07-01 · Cough, Healthy
What this study did
NCT05959447 · Bellus Health Inc. - a GSK company
2023-07-26 – 2023-10-13 · Cough, Healthy
What this study did
NCT05899829 · Bellus Health Inc. - a GSK company
2023-06-21 – 2023-08-08 · Cough, Healthy
What this study did
NCT06179537 · Bellus Health Inc. - a GSK company
2021-08-06 – 2021-11-21 · Healthy
What this study did
NCT05244759 · Bellus Health Inc. - a GSK company
2020-08-25 – 2021-03-02 · Healthy
What this study did
NCT03638180 · Bellus Health Inc. - a GSK company
2018-07-09 – 2018-10-25 · Cough
What this study did

Competitive landscape

No competitors sharing a mechanism or indication in the current universe.

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow BLU-5937 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
March 2027 (1)
Phase 2Irritable Bowel SyndromeRecruiting
Est. primary completion 2027-03-09 · NCT07519395 · CT.gov ↗
What to watch
August 2027 (1)
Phase 3Refractory Chronic CoughRecruiting
Est. primary completion 2027-08-27 · NCT07650084 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

17 July 2026Topline resultPhase 3 CALM-1 met, CALM-2 missed primary endpoint for camlipixant